Cirrhosis News and Research

Latest Cirrhosis News and Research

Allergan to jointly promote its adjustable gastric band for bariatric surgery with Covidien

Covidien, a leading global provider of healthcare products, today announced the extension of its agreement with Allergan, Inc. to jointly promote Allergan’s LAP-BAND® System, the top-selling adjustable gastric band for bariatric surgery, in the United States.

18 Jan 2010

Need for further studies on clinical characteristics of Intrahepatic Cholangiocarcinoma

Incidence of intrahepatic cholangiocarcinoma (ICC) is increasing worldwide and its prognosis is very poor. Thus, further studies on its clinical characteristics for early detection and on surgical treatment for better prognosis are urgently needed.

18 Jan 2010

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

With today's release of a landmark study by the Institute of Medicine (IOM), Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C, finding that inadequate public-health resources are being allocated to national and local prevention, control, and surveillance programs, the National Viral Hepatitis Roundtable (NVHR) today renewed its call for the Administration, Congress, and the entire health care system to take immediate and decisive action to implement the report's key recommendations.

12 Jan 2010

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

A recent study by doctors from the Hospital Cl-nic in Barcelona, Spain determined that repeated liver stiffness measurements (LSM) in the first year following liver transplant (LT) could discriminate between slow and rapid "fibrosers" (patients with fibrosis stage of F2-F4 one year post LT).

6 Jan 2010

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Researchers have identified two cellular proteins that are important factors in hepatitis C virus infection, a finding that may result in the approval of new and less toxic treatments for the disease, which can lead to liver cancer and cirrhosis.

6 Jan 2010

Increased coffee consumption linked to reduced hepatic fibrosis

Researchers from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) determined that patients with chronic hepatitis C virus (HCV) who consumed more than 308 mg of caffeine daily had milder liver fibrosis. The daily amount of caffeine intake found to be beneficial is equivalent to 2.25 cups of regular coffee.

5 Jan 2010

LifeVantage announces Protandim human clinical trials for non-alcoholic steatohepatitis

LifeVantage Corporation, the maker of Protandim® and TrueScience(TM) Anti-Aging Cream, science-based solutions to oxidative stress, announced today that the Company's flagship product, Protandim, a patented dietary supplement composed of five highly synergistic "indirect antioxidants", is currently the subject of two human clinical trials at the University of Colorado, Denver.

5 Jan 2010

BUSM researchers discover new gene therapy for treating emphysema patients

Researchers from Boston University School of Medicine (BUSM) have discovered a new gene therapy that may prevent the progression of emphysema. The study, which appears on-line in the Journal of Clinical Investigation, describes a method to express therapeutic genes in lung tissue for a lifetime after only a single treatment.

22 Dec 2009

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

17 Dec 2009

Novartis submits JOULFERON MAA to the EMEA

Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.

15 Dec 2009

Herb milk thistle help treat liver inflammation in cancer patients who receive chemotherapy, finds study

A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.

14 Dec 2009

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).

9 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in its phase II clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate).

3 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Siemens Healthcare to showcase latest medical imaging technologies at RSNA 2009

At the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), "Images, my way" will resonate throughout the Siemens Healthcare booth (#825) from November 29 to December 3 at McCormick Place (Booth #825, East Building/Lakeside Center, Hall D) in Chicago.

30 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

Cirrhosis News and Research

Latest Cirrhosis News and Research

Allergan to jointly promote its adjustable gastric band for bariatric surgery with Covidien

Need for further studies on clinical characteristics of Intrahepatic Cholangiocarcinoma

NVHR supports IOM report on inadequate federal funding for chronic viral hepatitis

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Increased coffee consumption linked to reduced hepatic fibrosis

LifeVantage announces Protandim human clinical trials for non-alcoholic steatohepatitis

BUSM researchers discover new gene therapy for treating emphysema patients

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

Novartis submits JOULFERON MAA to the EMEA

Herb milk thistle help treat liver inflammation in cancer patients who receive chemotherapy, finds study

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

New SPC3649 drug found effective in treating HCV infections

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Hyperion Therapeutics commences enrollment in its HPN-100 episodic hepatic encephalopathy trial

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Siemens Healthcare to showcase latest medical imaging technologies at RSNA 2009

Human Genome Sciences submits BLA for ZALBIN

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cirrhosis News and Research

Latest Cirrhosis News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in